21 results on '"Hinckley Stukovsky, Karen D"'
Search Results
2. Endothelin-1, cardiac morphology, and heart failure: the MESA angiogenesis study
- Author
-
Leary, Peter J., Jenny, Nancy S., Bluemke, David A., Kawut, Steven M., Kronmal, Richard A., Lima, Joao A., Maron, Bradley A., Ralph, David D., Rayner, Samuel G., Ryan, John J., Steinberg, Zachary L., Hinckley Stukovsky, Karen D., and Tedford, Ryan J.
- Published
- 2020
- Full Text
- View/download PDF
3. Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults
- Author
-
Garg, Parveen K, Arnold, Alice M, Hinckley Stukovsky, Karen D, Koro, Carol, Jenny, Nancy S, Mukamal, Kenneth J, Criqui, Michael H, Furberg, Curt D, Newman, Anne B, and Cushman, Mary
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Aging ,Atherosclerosis ,Cardiovascular ,Prevention ,Clinical Research ,1-Alkyl-2-acetylglycerophosphocholine Esterase ,Age Factors ,Aged ,Ankle Brachial Index ,Biomarkers ,Chi-Square Distribution ,Female ,Humans ,Incidence ,Inflammation Mediators ,Logistic Models ,Male ,Odds Ratio ,Peripheral Arterial Disease ,Prognosis ,Proportional Hazards Models ,Risk Assessment ,Risk Factors ,Time Factors ,United States ,Up-Regulation ,ankle-brachial index ,epidemiology ,inflammation ,lipoprotein-associated phospholipase A(2) ,peripheral artery disease ,ankle–brachial index ,lipoprotein-associated phospholipase A2 ,Cardiorespiratory Medicine and Haematology ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
ObjectiveAlthough prior studies report a relationship between elevated lipoprotein-associated phospholipase A2 (Lp-PLA2) and incident cardiovascular disease, the prospective association of Lp-PLA2 with incident peripheral arterial disease (PAD) has not been studied. We investigated the association between Lp-PLA2 mass and activity and the risk of developing clinical PAD and low ankle-brachial index (ABI).Approach and resultsAmong Cardiovascular Health Study participants, a population-based cohort of 5888 adults aged ≥65 years enrolled in 1989 to 1990, Lp-PLA2 mass and activity were measured in 4537 individuals without baseline PAD. Clinical PAD, defined as leg artery revascularization or diagnosed claudication, was ascertained through 2011. Incident low ABI, defined as ABI 0.9 at baseline and a second ABI measurement 3 or 6 years later. Analyses were adjusted for demographics, cholesterol, smoking, comorbidities, and C-reactive protein. Each standard deviation increment in Lp-PLA2 mass (117 ng/mL) was associated with a higher risk of developing clinical PAD (hazard ratio 1.28; 95% confidence interval 1.13, 1.45) and incident low ABI (odds ratio 1.16; 95% confidence interval 1.00, 1.33). Results per standard deviation increment in Lp-PLA2 activity (13 nmol/min per mL) were similar for clinical PAD (hazard ratio 1.24; 95% confidence interval 1.07, 1.44) and low ABI (odds ratio 1.28; 95% confidence interval 1.09, 1.50).ConclusionsHigher Lp-PLA2 mass and activity were associated with development of both incident clinical PAD and low ABI. Future studies are needed to determine whether pharmacological inhibition of Lp-PLA2 reduces the incidence of PAD.
- Published
- 2016
4. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial
- Author
-
Kerby, Gwen, Kopecky, Carol, Anthony, Meg, Mogayzel, Peter, Walker, Doug, Zeglin, Britany, Hoover, Wynton, Hathorne, Heather, Slaten, Katie, Dorkin, Henry (Hank), Fowler, Robert, Fenton, Cole (Nicolas), Ulles, Monica, Goetz, Danielle, Caci, Nadine, Cahill, Beth, Roach, Christine, Retsch-Bogart, George, Johnson, Robin, Cunnion, Rose, McColley, Susanna, Ward, Steven, Bell, Emily, McPhail, Gary, Keller, Kimberly, Thornton, Kelly, Parsons, Ashlee, Chmiel, James, Schaefer, Cindy, Tribout, Megan, Consiglio, Brittany, Tribout, Heather, McCoy, Karen, Johnson, Terri, Olson, Patti, Raterman, Laura, Hiatt, Peter, Walker, Betty, Schaap, Nicoline, Davis, Miriam, Davis, Stephanie, Clem, Charles, Bendy, Lisa, Starner, Tim, Lux, Cheri, Carver, Terrence, Jr., Thompson, Rose, Williams, April, Schmoll, Candy, Hastings, Patricia M., Noe, Julie, Roth, Laura, Kump, Theresa, McNamara, John, Franck Thompson, Elizabeth, Yousef, Shatha, Wezel, Germaine (Gigi), Oquendo, Omar, Darling, Amanda, Valencia, Wendy, Milla, Carlos, Zirbes, Jackie, Rubenstein, Ronald, Donnelly, Erin, Malpass, Jean, Weiner, Daniel, Agostini, Brittani, Hartigan, Elizabeth, Cornell, Alexandra, Klein, Brendan, Bucher, Jenna, Nusbaum, Pierce, Rosenfeld, Margaret, McNamara, Sharon, Genatossio, Alan, Pittman, Jessica, Hicks, Tina, Bauer, Irma, Siegel, Molly, Isaac, Sarah, Jensen, Renee, Au, Jacky, Stanojevic, Sanja, Ratjen, Felix, McDonald, Nancy, Prentice, Carley, Chilvers, Mark, Richmond, Melissa, Davis, Stephanie D, Kronmal, Richard A, Hinckley Stukovsky, Karen D, and Jorgensen, Neal
- Published
- 2019
- Full Text
- View/download PDF
5. Obstructive Sleep Apnea and Subclinical Interstitial Lung Disease in the Multi-Ethnic Study of Atherosclerosis (MESA)
- Author
-
Kim, John S., Podolanczuk, Anna J., Borker, Priya, Kawut, Steven M., Raghu, Ganesh, Kaufman, Joel D., Hinckley Stukovsky, Karen D., Hoffman, Eric A., Barr, Graham R., Gottlieb, Daniel J., Redline, Susan S., and Lederer, David J.
- Published
- 2017
- Full Text
- View/download PDF
6. Collaborative Cohort of Cohorts for COVID-19 Research (C4R) Study: Study Design
- Author
-
Oelsner, Elizabeth C, Krishnaswamy, Akshaya, Balte, Pallavi P, Allen, Norrina Bai, Ali, Tauqeer, Anugu, Pramod, Andrews, Howard F, Arora, Komal, Asaro, Alyssa, Barr, R Graham, Bertoni, Alain G, Bon, Jessica, Boyle, Rebekah, Chang, Arunee A, Chen, Grace, Coady, Sean, Cole, Shelley A, Coresh, Josef, Cornell, Elaine, Correa, Adolfo, Couper, David, Cushman, Mary, Demmer, Ryan T, Elkind, Mitchell SV, Folsom, Aaron R, Fretts, Amanda M, Gabriel, Kelley P, Gallo, Linda C, Gutierrez, Jose, Han, Mei Lan K, Henderson, Joel M, Howard, Virginia J, Isasi, Carmen R, Jacobs, David R, Judd, Suzanne E, Mukaz, Debora Kamin, Kanaya, Alka M, Kandula, Namratha R, Kaplan, Robert C, Kinney, Gregory L, Kucharska-Newton, Anna, Lee, Joyce S, Lewis, Cora E, Levine, Deborah A, Levitan, Emily B, Levy, Bruce D, Make, Barry J, Malloy, Kimberly, Manly, Jennifer J, Mendoza-Puccini, Carolina, Meyer, Katie A, Min, Yuan-I Nancy, Moll, Matthew R, Moore, Wendy C, Mauger, David, Ortega, Victor E, Palta, Priya, Parker, Monica M, Phipatanakul, Wanda, Post, Wendy S, Postow, Lisa, Psaty, Bruce M, Regan, Elizabeth A, Ring, Kimberly, Roger, Véronique L, Rotter, Jerome I, Rundek, Tatjana, Sacco, Ralph L, Schembri, Michael, Schwartz, David A, Seshadri, Sudha, Shikany, James M, Sims, Mario, Hinckley Stukovsky, Karen D, Talavera, Gregory A, Tracy, Russell P, Umans, Jason G, Vasan, Ramachandran S, Watson, Karol E, Wenzel, Sally E, Winters, Karen, Woodruff, Prescott G, Xanthakis, Vanessa, Zhang, Ying, Zhang, Yiyi, and C4R Investigators
- Subjects
Adult ,Pediatric Research Initiative ,C4R Investigators ,Adolescent ,Epidemiology ,Medical and Health Sciences ,Mathematical Sciences ,Cohort Studies ,Vaccine Related ,Young Adult ,coronavirus disease 2019 ,severe acute respiratory syndrome coronavirus 2 , Clinical Research ,Biodefense ,Behavioral and Social Science ,80 and over ,Humans ,Prospective Studies ,Aetiology ,%22">> ,Pandemics ,Lung ,Aged ,SARS-CoV-2 ,Prevention ,COVID-19 ,Pneumonia ,Middle Aged ,United States ,Infectious Diseases ,Emerging Infectious Diseases ,Good Health and Well Being ,severe acute respiratory syndrome coronavirus 2 ,2.4 Surveillance and distribution - Abstract
The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) is a national prospective study of adults comprising 14 established US prospective cohort studies. Starting as early as 1971, investigators in the C4R cohort studies have collected data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health. C4R links this pre-coronavirus disease 2019 (COVID-19) phenotyping to information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute and postacute COVID-related illness. C4R is largely population-based, has an age range of 18-108 years, and reflects the racial, ethnic, socioeconomic, and geographic diversity of the United States. C4R ascertains SARS-CoV-2 infection and COVID-19 illness using standardized questionnaires, ascertainment of COVID-related hospitalizations and deaths, and a SARS-CoV-2 serosurvey conducted via dried blood spots. Master protocols leverage existing robust retention rates for telephone and in-person examinations and high-quality event surveillance. Extensive prepandemic data minimize referral, survival, and recall bias. Data are harmonized with research-quality phenotyping unmatched by clinical and survey-based studies; these data will be pooled and shared widely to expedite collaboration and scientific findings. This resource will allow evaluation of risk and resilience factors for COVID-19 severity and outcomes, including postacute sequelae, and assessment of the social and behavioral impact of the pandemic on long-term health trajectories.
- Published
- 2022
7. The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial
- Author
-
Tiddens, Harm A W M, primary, Chen, Yuxin, additional, Andrinopoulou, Eleni-Rosalina, additional, Davis, Stephanie D, additional, Rosenfeld, Margaret, additional, Ratjen, Felix, additional, Kronmal, Richard A, additional, Hinckley Stukovsky, Karen D, additional, Dasiewicz, Alison, additional, Stick, Stephen Michael, additional, Anthony, Margaret M., additional, Au, Jacky, additional, Belessis, Yvonne, additional, Bonte, Merlijn, additional, Cheney, Joyce, additional, Clem, Charles, additional, Clements, Barry, additional, Cooper, Peter, additional, Davis, Stephanie D., additional, Davis, Miriam, additional, de Boeck, Kris, additional, de Marchis, Matteo, additional, De Wachter, Elke, additional, Delaisi, Bertrand, additional, Delaup, Véronique, additional, DeRicco, Adrienne, additional, Foti, Alexia, additional, Gan, Richard, additional, Garriga, Laura, additional, Gartner, Silvia, additional, Genatossio, Alan, additional, Grogan, Sam, additional, Hilton, Jodi, additional, Hoppe, Jordana E., additional, Janssens, Hettie M., additional, Jensen, Renee, additional, Johnson, Robin, additional, Kemner-van de Corput, Mariette P.C., additional, Klein, Brendan, additional, Kronmal, Richard A., additional, Lucca, Francesca, additional, Lucidi, Vincencina, additional, Montemitro, Enza, additional, Nahidi, Lily, additional, Nielsen, Kim G., additional, Pearce, Kasey, additional, Pittman, Jessica E, additional, Powers, Michael, additional, Prentice, Carley, additional, Pressler, Tania, additional, Rayment, Jonathan H, additional, Reix, Philippe, additional, Retsch-Bogart, George, additional, Riera, Luis, additional, Robinson, Phil, additional, Robinson, Paul, additional, Sanders, Don B., additional, Sandoval, Rodrigo A., additional, Sandvik, Rikke Mulvad, additional, Saunders, Clare, additional, Siegel, Molly, additional, Smith, Julie, additional, Solomon, Melinda, additional, Stanojevic, Sanja, additional, Tai, Andrew, additional, Tiddens, Harm A.W.M., additional, van de Puttelaar, Jorien, additional, Van den Brande, Christel, additional, van Straten, Marcel, additional, Vermeulen, Francois, additional, Volpi, Sonia, additional, Wainwright, Claire E., additional, Weiner, Daniel J., additional, Yuan, Yi, additional, and Zaimeddine, Sarah, additional
- Published
- 2022
- Full Text
- View/download PDF
8. Genome-Wide Study of Percent Emphysema on Computed Tomography in the General Population. The Multi-Ethnic Study of Atherosclerosis Lung/SNP Health Association Resource Study
- Author
-
Manichaikul, Ani, Hoffman, Eric A., Smolonska, Joanna, Gao, Wei, Cho, Michael H., Baumhauer, Heather, Budoff, Matthew, Austin, John H. M., Washko, George R., Carr, Jeffrey J., Kaufman, Joel D., Pottinger, Tess, Powell, Charles A., Wijmenga, Cisca, Zanen, Pieter, Groen, Harry J. M., Postma, Dirkje S., Wanner, Adam, Rouhani, Farshid N., Brantly, Mark L., Powell, Rhea, Smith, Benjamin M., Rabinowitz, Dan, Raffel, Leslie J., Hinckley Stukovsky, Karen D., Crapo, James D., Beaty, Terri H., Hokanson, John E., Silverman, Edwin K., Dupuis, Josée, OʼConnor, George T., Boezen, Marike H., Rich, Stephen S., and Barr, Graham R.
- Published
- 2014
- Full Text
- View/download PDF
9. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial
- Author
-
Ratjen, Felix, primary, Davis, Stephanie D, additional, Stanojevic, Sanja, additional, Kronmal, Richard A, additional, Hinckley Stukovsky, Karen D, additional, Jorgensen, Neal, additional, Rosenfeld, Margaret, additional, Kerby, Gwen, additional, Kopecky, Carol, additional, Anthony, Meg, additional, Mogayzel, Peter, additional, Walker, Doug, additional, Zeglin, Britany, additional, Hoover, Wynton, additional, Hathorne, Heather, additional, Slaten, Katie, additional, Dorkin, Henry (Hank), additional, Fowler, Robert, additional, Fenton, Cole (Nicolas), additional, Ulles, Monica, additional, Goetz, Danielle, additional, Caci, Nadine, additional, Cahill, Beth, additional, Roach, Christine, additional, Retsch-Bogart, George, additional, Johnson, Robin, additional, Cunnion, Rose, additional, McColley, Susanna, additional, Ward, Steven, additional, Bell, Emily, additional, McPhail, Gary, additional, Keller, Kimberly, additional, Thornton, Kelly, additional, Parsons, Ashlee, additional, Chmiel, James, additional, Schaefer, Cindy, additional, Tribout, Megan, additional, Consiglio, Brittany, additional, Tribout, Heather, additional, McCoy, Karen, additional, Johnson, Terri, additional, Olson, Patti, additional, Raterman, Laura, additional, Hiatt, Peter, additional, Walker, Betty, additional, Schaap, Nicoline, additional, Davis, Miriam, additional, Davis, Stephanie, additional, Clem, Charles, additional, Bendy, Lisa, additional, Starner, Tim, additional, Lux, Cheri, additional, Carver, Terrence, additional, Thompson, Rose, additional, Williams, April, additional, Schmoll, Candy, additional, Hastings, Patricia M., additional, Noe, Julie, additional, Roth, Laura, additional, Kump, Theresa, additional, McNamara, John, additional, Franck Thompson, Elizabeth, additional, Yousef, Shatha, additional, Wezel, Germaine (Gigi), additional, Oquendo, Omar, additional, Darling, Amanda, additional, Valencia, Wendy, additional, Milla, Carlos, additional, Zirbes, Jackie, additional, Rubenstein, Ronald, additional, Donnelly, Erin, additional, Malpass, Jean, additional, Weiner, Daniel, additional, Agostini, Brittani, additional, Hartigan, Elizabeth, additional, Cornell, Alexandra, additional, Klein, Brendan, additional, Bucher, Jenna, additional, Nusbaum, Pierce, additional, McNamara, Sharon, additional, Genatossio, Alan, additional, Pittman, Jessica, additional, Hicks, Tina, additional, Bauer, Irma, additional, Siegel, Molly, additional, Isaac, Sarah, additional, Jensen, Renee, additional, Au, Jacky, additional, Ratjen, Felix, additional, McDonald, Nancy, additional, Prentice, Carley, additional, Chilvers, Mark, additional, and Richmond, Melissa, additional
- Published
- 2019
- Full Text
- View/download PDF
10. Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults: The Cardiovascular Health Study
- Author
-
Garg, Parveen K, Arnold, Alice M, Hinckley Stukovsky, Karen D, Koro, Carol, Jenny, Nancy S, Mukamal, Kenneth J, Criqui, Michael H, Furberg, Curt D, Newman, Anne B, and Cushman, Mary
- Subjects
Male ,Aging ,Time Factors ,Clinical Sciences ,Cardiorespiratory Medicine and Haematology ,peripheral artery disease ,Cardiovascular ,Risk Assessment ,Peripheral Arterial Disease ,Risk Factors ,Clinical Research ,Odds Ratio ,Humans ,ankle-brachial index ,lipoprotein-associated phospholipase A(2) ,Ankle Brachial Index ,lipoprotein-associated phospholipase A2 ,Proportional Hazards Models ,Aged ,Chi-Square Distribution ,ankle–brachial index ,Incidence ,Prevention ,Age Factors ,Prognosis ,Atherosclerosis ,United States ,Up-Regulation ,Logistic Models ,Cardiovascular System & Hematology ,inflammation ,1-Alkyl-2-acetylglycerophosphocholine Esterase ,Female ,epidemiology ,Inflammation Mediators ,Biomarkers - Abstract
ObjectiveAlthough prior studies report a relationship between elevated lipoprotein-associated phospholipase A2 (Lp-PLA2) and incident cardiovascular disease, the prospective association of Lp-PLA2 with incident peripheral arterial disease (PAD) has not been studied. We investigated the association between Lp-PLA2 mass and activity and the risk of developing clinical PAD and low ankle-brachial index (ABI).Approach and resultsAmong Cardiovascular Health Study participants, a population-based cohort of 5888 adults aged ≥65 years enrolled in 1989 to 1990, Lp-PLA2 mass and activity were measured in 4537 individuals without baseline PAD. Clinical PAD, defined as leg artery revascularization or diagnosed claudication, was ascertained through 2011. Incident low ABI, defined as ABI 0.9 at baseline and a second ABI measurement 3 or 6 years later. Analyses were adjusted for demographics, cholesterol, smoking, comorbidities, and C-reactive protein. Each standard deviation increment in Lp-PLA2 mass (117 ng/mL) was associated with a higher risk of developing clinical PAD (hazard ratio 1.28; 95% confidence interval 1.13, 1.45) and incident low ABI (odds ratio 1.16; 95% confidence interval 1.00, 1.33). Results per standard deviation increment in Lp-PLA2 activity (13 nmol/min per mL) were similar for clinical PAD (hazard ratio 1.24; 95% confidence interval 1.07, 1.44) and low ABI (odds ratio 1.28; 95% confidence interval 1.09, 1.50).ConclusionsHigher Lp-PLA2 mass and activity were associated with development of both incident clinical PAD and low ABI. Future studies are needed to determine whether pharmacological inhibition of Lp-PLA2 reduces the incidence of PAD.
- Published
- 2016
11. Plasma Soluble Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis
- Author
-
Manichaikul, Ani, primary, Sun, Li, additional, Borczuk, Alain C., additional, Onengut-Gumuscu, Suna, additional, Farber, Emily A., additional, Mathai, Susan K., additional, Zhang, Weiming, additional, Raghu, Ganesh, additional, Kaufman, Joel D., additional, Hinckley-Stukovsky, Karen D., additional, Kawut, Steven M., additional, Jelic, Sanja, additional, Liu, Wen, additional, Fingerlin, Tasha E., additional, Schwartz, David A., additional, Sell, Jessica L., additional, Rich, Stephen S., additional, Barr, R. Graham, additional, and Lederer, David J., additional
- Published
- 2017
- Full Text
- View/download PDF
12. Secondhand Smoke Exposure and Subclinical Cardiovascular Disease: The Multi‐Ethnic Study of Atherosclerosis
- Author
-
Jones, Miranda R., primary, Magid, Hoda S., additional, Al‐Rifai, Mahmoud, additional, McEvoy, John W., additional, Kaufman, Joel D., additional, Hinckley Stukovsky, Karen D., additional, Szklo, Moyses, additional, Polak, Joseph, additional, Burke, Gregory L., additional, Post, Wendy S., additional, Blaha, Michael J., additional, and Navas‐Acien, Ana, additional
- Published
- 2016
- Full Text
- View/download PDF
13. Lipoprotein-Associated Phospholipase A 2 and Incident Peripheral Arterial Disease in Older Adults
- Author
-
Garg, Parveen K., primary, Arnold, Alice M., additional, Hinckley Stukovsky, Karen D., additional, Koro, Carol, additional, Jenny, Nancy S., additional, Mukamal, Kenneth J., additional, Criqui, Michael H., additional, Furberg, Curt D., additional, Newman, Anne B., additional, and Cushman, Mary, additional
- Published
- 2016
- Full Text
- View/download PDF
14. Genome-wide association study of subclinical interstitial lung disease in MESA.
- Author
-
Manichaikul, Ani, Xin-Qun Wang, Li Sun, Dupuis, Josée, Borczuk, Alain C., Nguyen, Jennifer N., Raghu, Ganesh, Hoffman, Eric A., Onengut-Gumuscu, Suna, Farber, Emily A., Kaufman, Joel D., Rabinowitz, Dan, Hinckley Stukovsky, Karen D., Kawut, Steven M., Hunninghake, Gary M., Washko, George R., O'Connor, George T., Rich, Stephen S., Barr, R. Graham, and Lederer, David J.
- Subjects
INTERSTITIAL lung diseases ,COMPUTED tomography ,CELL cycle ,GLYCOSYLATION ,CELL adhesion ,GENETICS ,ASIANS ,BLACK people ,COMPARATIVE studies ,GENETIC polymorphisms ,HISPANIC Americans ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,PUBLIC health surveillance ,RESEARCH ,RESEARCH funding ,WHITE people ,EVALUATION research ,SEQUENCE analysis ,DIAGNOSIS - Abstract
Background: We conducted a genome-wide association study (GWAS) of subclinical interstitial lung disease (ILD), defined as high attenuation areas (HAA) on CT, in the population-based Multi-Ethnic Study of Atherosclerosis Study.Methods: We measured the percentage of high attenuation areas (HAA) in the lung fields on cardiac CT scan defined as voxels with CT attenuation values between -600 and -250 HU. Genetic analyses were performed in MESA combined across race/ethnic groups: non-Hispanic White (n = 2,434), African American (n = 2,470), Hispanic (n = 2,065) and Chinese (n = 702), as well as stratified by race/ethnicity.Results: Among 7,671 participants, regions at genome-wide significance were identified for basilar peel-core ratio of HAA in FLJ35282 downstream of ANRIL (rs7852363, P = 2.1x10-9) and within introns of SNAI3-AS1 (rs140142658, P = 9.6x10-9) and D21S2088E (rs3079677, P = 2.3x10-8). Within race/ethnic groups, 18 additional loci were identified at genome-wide significance, including genes related to development (FOXP4), cell adhesion (ALCAM) and glycosylation (GNPDA2, GYPC, GFPT1 and FUT10). Among these loci, SNP rs6844387 near GNPDA2 demonstrated nominal evidence of replication in analysis of n = 1,959 participants from the Framingham Heart Study (P = 0.029). FOXP4 region SNP rs2894439 demonstrated evidence of validation in analysis of n = 228 White ILD cases from the Columbia ILD Study compared to race/ethnicity-matched controls from MESA (one-sided P = 0.007). In lung tissue from 15 adults with idiopathic pulmonary fibrosis compared to 15 adults without lung disease. ANRIL (P = 0.001), ALCAM (P = 0.03) and FOXP4 (P = 0.046) were differentially expressed.Conclusions: Our results suggest novel roles for protein glycosylation and cell cycle disinhibition by long non-coding RNA in the pathogenesis of ILD. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
15. Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults.
- Author
-
Garg, Parveen K., Arnold, Alice M., Hinckley Stukovsky, Karen D., Koro, Carol, Jenny, Nancy S., Mukamal, Kenneth J., Criqui, Michael H., Furberg, Curt D., Newman, Anne B., and Cushman, Mary
- Published
- 2016
- Full Text
- View/download PDF
16. Longitudinal Lung Function Effects Of Fine Particulate Matter In Children With Cystic Fibrosis
- Author
-
Hinckley Stukovsky, Karen D., primary, Sheppard, Lianne, additional, Caldwell, Ellen S., additional, Vedal, Sverre, additional, Kaufman, Joel D., additional, and Goss, Christopher H., additional
- Published
- 2010
- Full Text
- View/download PDF
17. Lipoprotein-Associated Phospholipase A2and Incident Peripheral Arterial Disease in Older Adults
- Author
-
Garg, Parveen K., Arnold, Alice M., Hinckley Stukovsky, Karen D., Koro, Carol, Jenny, Nancy S., Mukamal, Kenneth J., Criqui, Michael H., Furberg, Curt D., Newman, Anne B., and Cushman, Mary
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2016
- Full Text
- View/download PDF
18. A Pilot Randomized Clinical Trial of Pediatric Cystic Fibrosis Pulmonary Exacerbations Treatment Strategies.
- Author
-
Sanders DB, Bartz TM, Zemanick ET, Hoppe JE, Hinckley Stukovsky KD, Cogen JD, Bendy L, McNamara S, Enright E, Kime NA, Kronmal RA, Edwards TC, Morgan WJ, and Rosenfeld M
- Subjects
- Humans, Child, Pilot Projects, Anti-Bacterial Agents therapeutic use, Administration, Inhalation, Administration, Oral, Cystic Fibrosis drug therapy
- Abstract
Rationale: Despite the high prevalence and clear morbidity of cystic fibrosis (CF) pulmonary exacerbations (PEx), there have been no published clinical trials of outpatient exacerbation management. Objectives: To assess the feasibility of a pediatric clinical trial in which treatment of mild PEx is assigned randomly to immediate oral antibiotics or tailored therapy (increased airway clearance alone with oral antibiotics added only for prespecified criteria). The outcome on which sample size was based was the proportion of tailored therapy participants who avoided oral antibiotics during the 28 days after randomization. Methods: In this randomized, open-label, pilot feasibility study at 10 U.S. sites, children 6-18 years of age with CF were enrolled at their well baseline visits and followed through their first randomized PEx. Results: One hundred twenty-one participants were enrolled, of whom 94 (78%) reported symptoms of PEx at least once; of these, 81 (86%) had at least one exacerbation that met randomization criteria, of whom 63 (78%) were randomized. Feasibility goals were met, including enrollment, early detection of symptoms of PEx, and ability to randomize. Among the 33 participants assigned to tailored therapy, 10 (30%) received oral antibiotics, while 29 of 30 (97%) assigned to immediate antibiotics received oral antibiotics. The avoidance of oral antibiotics in 70% (95% confidence interval, 54-85%) was statistically significantly different from our null hypothesis that <10% of participants assigned to the tailored therapy arm would avoid antibiotics. Conclusions: Our pilot study demonstrates that conducting a randomized trial of oral antibiotic treatment strategies for mild PEx in children with CF is feasible and that assignment to a tailored therapy arm may reduce antibiotic exposure. Clinical trial registered with www.clinicaltrials.gov (NCT04608019).
- Published
- 2023
- Full Text
- View/download PDF
19. Collaborative Cohort of Cohorts for COVID-19 Research (C4R) Study: Study Design.
- Author
-
Oelsner EC, Krishnaswamy A, Balte PP, Allen NB, Ali T, Anugu P, Andrews HF, Arora K, Asaro A, Barr RG, Bertoni AG, Bon J, Boyle R, Chang AA, Chen G, Coady S, Cole SA, Coresh J, Cornell E, Correa A, Couper D, Cushman M, Demmer RT, Elkind MSV, Folsom AR, Fretts AM, Gabriel KP, Gallo LC, Gutierrez J, Han MLK, Henderson JM, Howard VJ, Isasi CR, Jacobs DR Jr, Judd SE, Mukaz DK, Kanaya AM, Kandula NR, Kaplan RC, Kinney GL, Kucharska-Newton A, Lee JS, Lewis CE, Levine DA, Levitan EB, Levy BD, Make BJ, Malloy K, Manly JJ, Mendoza-Puccini C, Meyer KA, Min YN, Moll MR, Moore WC, Mauger D, Ortega VE, Palta P, Parker MM, Phipatanakul W, Post WS, Postow L, Psaty BM, Regan EA, Ring K, Roger VL, Rotter JI, Rundek T, Sacco RL, Schembri M, Schwartz DA, Seshadri S, Shikany JM, Sims M, Hinckley Stukovsky KD, Talavera GA, Tracy RP, Umans JG, Vasan RS, Watson KE, Wenzel SE, Winters K, Woodruff PG, Xanthakis V, Zhang Y, and Zhang Y
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Cohort Studies, Humans, Middle Aged, Pandemics, Prospective Studies, SARS-CoV-2, United States epidemiology, Young Adult, COVID-19 epidemiology
- Abstract
The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) is a national prospective study of adults comprising 14 established US prospective cohort studies. Starting as early as 1971, investigators in the C4R cohort studies have collected data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health. C4R links this pre-coronavirus disease 2019 (COVID-19) phenotyping to information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute and postacute COVID-related illness. C4R is largely population-based, has an age range of 18-108 years, and reflects the racial, ethnic, socioeconomic, and geographic diversity of the United States. C4R ascertains SARS-CoV-2 infection and COVID-19 illness using standardized questionnaires, ascertainment of COVID-related hospitalizations and deaths, and a SARS-CoV-2 serosurvey conducted via dried blood spots. Master protocols leverage existing robust retention rates for telephone and in-person examinations and high-quality event surveillance. Extensive prepandemic data minimize referral, survival, and recall bias. Data are harmonized with research-quality phenotyping unmatched by clinical and survey-based studies; these data will be pooled and shared widely to expedite collaboration and scientific findings. This resource will allow evaluation of risk and resilience factors for COVID-19 severity and outcomes, including postacute sequelae, and assessment of the social and behavioral impact of the pandemic on long-term health trajectories., (Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health 2022. This work is written by (a) US Government employee(s) and is in the public domain in the US.)
- Published
- 2022
- Full Text
- View/download PDF
20. Collaborative Cohort of Cohorts for COVID-19 Research (C4R) Study: Study Design.
- Author
-
Oelsner EC, Allen NB, Ali T, Anugu P, Andrews H, Asaro A, Balte PP, Barr RG, Bertoni AG, Bon J, Boyle R, Chang AA, Chen G, Cole SA, Coresh J, Cornell E, Correa A, Couper D, Cushman M, Demmer RT, Elkind MSV, Folsom AR, Fretts AM, Gabriel KP, Gallo L, Gutierrez J, Han MK, Henderson JM, Howard VJ, Isasi CR, Jacobs DR, Judd SE, Mukaz DK, Kanaya AM, Kandula NR, Kaplan R, Krishnaswamy A, Kinney GL, Kucharska-Newton A, Lee JS, Lewis CE, Levine DA, Levitan EB, Levy B, Make B, Malloy K, Manly JJ, Meyer KA, Min YI, Moll M, Moore WC, Mauger D, Ortega VE, Palta P, Parker MM, Phipatanakul W, Post W, Psaty BM, Regan EA, Ring K, Roger VL, Rotter JI, Rundek T, Sacco RL, Schembri M, Schwartz DA, Seshadri S, Shikany JM, Sims M, Hinckley Stukovsky KD, Talavera GA, Tracy RP, Umans JG, Vasan RS, Watson K, Wenzel SE, Winters K, Woodruff PG, Xanthakis V, Zhang Y, and Zhang Y
- Abstract
The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) is a national prospective study of adults at risk for coronavirus disease 2019 (COVID-19) comprising 14 established United States (US) prospective cohort studies. For decades, C4R cohorts have collected extensive data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health. C4R will link this pre-COVID phenotyping to information on SARS-CoV-2 infection and acute and post-acute COVID-related illness. C4R is largely population-based, has an age range of 18-108 years, and broadly reflects the racial, ethnic, socioeconomic, and geographic diversity of the US. C4R is ascertaining severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19 illness using standardized questionnaires, ascertainment of COVID-related hospitalizations and deaths, and a SARS-CoV-2 serosurvey via dried blood spots. Master protocols leverage existing robust retention rates for telephone and in-person examinations, and high-quality events surveillance. Extensive pre-pandemic data minimize referral, survival, and recall bias. Data are being harmonized with research-quality phenotyping unmatched by clinical and survey-based studies; these will be pooled and shared widely to expedite collaboration and scientific findings. This unique resource will allow evaluation of risk and resilience factors for COVID-19 severity and outcomes, including post-acute sequelae, and assessment of the social and behavioral impact of the pandemic on long-term trajectories of health and aging.
- Published
- 2021
- Full Text
- View/download PDF
21. Performance of maximum inspiratory pressure tests and maximum inspiratory pressure reference equations for 4 race/ethnic groups.
- Author
-
Sachs MC, Enright PL, Hinckley Stukovsky KD, Jiang R, and Barr RG
- Subjects
- Aged, Aged, 80 and over, Diaphragm, Female, Humans, Inspiratory Capacity, Male, Middle Aged, Models, Biological, Reference Values, United States, Ethnicity, Exhalation, Inhalation, Muscle Weakness diagnosis, Muscle Weakness ethnology
- Abstract
Background: Maximum inspiratory pressure (MIP) is an important and noninvasive index of diaphragm strength and an independent predictor of all-cause mortality. The ability of adults over a wide age range and multiple race/ethnicities to perform MIP tests has previously not been evaluated., Methods: The Multi-Ethnic Study of Atherosclerosis recruited white, African American, Hispanic, and Chinese American participants, ages 45-84 years, and free of clinical cardiovascular disease in 6 United States cities. MIP was measured using standard techniques among 3,849 Multi-Ethnic Study of Atherosclerosis participants. The MIP quality goal was 5 maneuvers, with the 2 largest values matching within 10 cm H2O. Correlates of MIP quality and values were assessed in logistic and linear regression models., Results: The 3,849 participants with MIP measures were 51% female, 35% white, 26% African American, 23% Hispanic, and 16% Chinese American. Mean+/-SD MIP was 73+/-26 cm H2O for women and 97+/-29 cm H2O for men. The quality goal was achieved by 83% of the cohort and was associated with female sex, older age, race/ethnicity, study site, low ratio of forced expiratory volume in the first second to forced vital capacity (FEV1/FVC), and wheeze with dyspnea. The multivariate correlates of MIP were male sex, younger age, higher body mass index, shorter height, higher FVC, higher systolic blood pressure (in women) and health status (in men). There were no clinically important race/ethnic differences in MIP values., Conclusions: Race-specific reference equations for MIP are unnecessary in the United States. More than 80% of adults can be successfully coached for 5 maneuvers, with repeatability within 10 cm H2O.
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.